Biomarkers
BIOL-40258
Biomarkers
Course Overview
As an emerging topic of discussion within clinical diagnosis and drug discovery, biomarker research and developments are set to expand the scope of relevant clinical endpoints. Participants in this course will gain a basic understanding of the study of biomarkers, as well as major concepts within the field.
Instruction from leading industry experts will deliver biomarker research and theoretical concepts, as well as practical issues involved in conducting drug discovery related biomarker research and disease related biomarker identification. Participants will learn various biomarker research model systems and tools while learning the criteria required for identifying biomarkers in different diseases.
Topics include:
- Biomarker requirements, classification and criteria for evaluating potential markers.
- The practice of sample collection and quality control for a biomarker study in conjunction with epidemiological studies, including design, analysis and more.
- Ethical and legal concerns.
- Biomarker analyses tools including flow cytometry, digital pathology, ligand binding, DNA arrays, gene expression arrays and proteomics.
- Biomarker in diseases, including cancer and autoimmune disease, such as rheumatoid arthritis.
- Biomarker in Drug Discovery in animal models, in vitro diagnostics and surrogate and endpoint biomarker.
Speakers
- Jelveh Lameh, Ph.D., Head of Translational Research, Zai Lab
- Hua Gong, M.D. Ph.D., V.P., Translational Medicine, BridgeBio Oncology Therapeutic
- Nathan Riccitelli, Ph.D., Associate Director, Innovative Technologies, Navigate BioPharma Services Inc.
- Naveen Dakappagari, Ph.D., Head, Biomarker and Diagnostic Development, Navigate BioPharma Services Inc.
- Chad Ray, Ph.D., Executive Director and Head of Discovery Sciences and Technologies, Zoetis
Course Format
This course is offered in a live online format using Zoom conference technology. Please note that attendance in the live sessions and participation in the class project are mandatory.
Course Information
Course sessions
Section ID:
Class type:
Textbooks:
All course materials are included unless otherwise stated.
Policies:
- No refunds after: 4/21/2025
Schedule:
| Date | Day | Start | End |
|---|---|---|---|
| 4/14/2025 | Mon | 3:00 p.m. | 5:00 p.m. |
| 4/17/2025 | Thu | 3:00 p.m. | 5:00 p.m. |
| 4/21/2025 | Mon | 3:00 p.m. | 5:00 p.m. |
| 4/24/2025 | Thu | 3:00 p.m. | 5:00 p.m. |
| 4/28/2025 | Mon | 3:00 p.m. | 5:00 p.m. |
| 5/1/2025 | Thu | 3:00 p.m. | 5:00 p.m. |
| 5/5/2025 | Mon | 3:00 p.m. | 5:00 p.m. |
| 5/8/2025 | Thu | 3:00 p.m. | 5:00 p.m. |
| 5/12/2025 | Mon | 3:00 p.m. | 5:00 p.m. |
| 5/15/2025 | Thu | 3:00 p.m. | 5:00 p.m. |
| 5/19/2025 | Mon | 3:00 p.m. | 5:00 p.m. |
| 5/22/2025 | Thu | 3:00 p.m. | 5:00 p.m. |
Instructor:
Jelveh Lameh, Ph.D. in Pharmacology & Toxicology from UC Davis
Director of BioPharma Services, Genoptix Medical Laboratory
Jelveh Lameh, Ph.D. has over 30 years of experience in both academia and the biotech/pharmaceutical industry, holding various leadership roles. In academia, she served as an Assistant Professor at the University of California, San Francisco (UCSF), and as Head of In Vitro Pharmacology at MRI, where she led teams in neuropharmacology, drug discovery, and receptor pharmacology. She also served as the Principal Investigator (PI) on several NIH grants.
At biotech/ pharmaceutical industry, Dr. Lameh has held various leadership positions including Head of BioPharma Laboratory, Head of Operations and Regulatory Affairs, Chief Information Officer, VP of Regulatory & Quality Compliance, and Head of Translational Research. Dr. Lameh has led the development and implementation of hundreds of novel cancer diagnostic assays for clinical trials and as PI or Co-PI, contributed to the validation of several companion diagnostics.
Dr. Lameh has authored over 50 peer-reviewed articles and possesses expertise in biomarker discovery & development, in vitro diagnostics, companion diagnostics, drug development, molecular pharmacology, and cell signaling.
Dr. Lameh earned her Ph.D. in Pharmacology & Toxicology from the University of California, Davis, and completed her postdoctoral training at UC San Francisco.
